It seems hardly any of the new patients were assessable. It will be interesting to see if they have enough data for a shot at phase 2 being approved as a registrational study.
Don't see any reference to it. Though it seems that there has been a tempering of over exuberantly forward looking statements.
Still it looks like a marked improvement on SOC.
I personally prefer the more reality balanced and fact based communication style. Let the data talk and leave the supposition to oneself.
PTX Price at posting:
7.6¢ Sentiment: None Disclosure: Held
